Prospective Phase 0 Pilot Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients

Description:

The goal of the study is to assess how [68Ga]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, [68Ga]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using [177Lu]/[90Y] PentixaTher.

Sponsor:

Institut Cancerologie de l'Ouest

Contacts:

CAROLINE ROUSSEAU, MD, PhD

caroline.rousseau@ico.unicancer.fr

+33 2 40 67 99 31

NADIA ALLAM, PhD

nadia.allam@ico.unicancer.fr

+33 2 40 67 98 26

[68Ga]Ga-Pentixafor

Isotope(s):
Target(s):
  • CXCR4
Ligand: Small Molecules
Chelator: DOTA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468